FDA approves 1st test for opioid disorder screening

(CNN)– The Food and Drug Administration has approved a tool that uses genetic testing to help assess whether certain people are at risk of developing opioid use disorder.

The Autogenomics AdvertD test is meant for adults considering a short-term course of oral opioid pain meds, such as after a planned surgical procedure.

It uses a cheek swab sample to analyze 15 genetic markers involved in the brain’s reward pathways and associated with addiction.

It can be prescribed only to people who have no prior use of opioids and patients must consent to the test.

It’s not meant for those who are being treated for chronic pain.